Atrium Therapeutics Advances RNA Cardiovascular Collaboration with BMSd
Atrium Therapeutics, Inc., a biopharmaceutical company dedicated to delivering RNA therapeutics to the heart, announced it has earned another $15 million milestone payment from Bristol Myers Squibb based on the successful delivery of a lead compound targeting an undisclosed cardiology indication under the Company's on…
